Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi US

www.sanofi.us

Latest From Sanofi US

Sanofi Maintains Growth Streak But Oncology Pipeline Renewal Efforts Stall

The French major saw strong Q3 sales and raised its business guidance accordingly, but the discontinuation of an early-stage trial has added to a growing list of setbacks the firm has faced in reviving its oncology pipeline.

Sales & Earnings Companies

Ranitidine Litigation Opens With Settlements, But Still Massive With State And MDL Trials Pending

GSK and Sanofi will continue to defend against all claims alleging ranitidine increased risk of cancer. Four Rx generic firms reach settlements in first case scheduled for trial. Former US OTC Zantac marketers GSK and Sanofi, which markets the Zantac OTC brand in the US, along with former Rx brand marketer Pfizer could pay $1bn to $2bn each in potential settlements, analyst predicts.

Ingredients Legal Issues

Massive Zantac Product Liability Litigation Advances After Initial Settlements

GlaxoSmithKline will continue to defend itself against all claims alleging ranitidine increased the risk of cancer. Four generic firms reach settlements in the first case that had been scheduled for trial. GSK, Sanofi and Pfizer could pay $1bn-$2bn each in potential settlements, an analyst predicts.

Drug Safety Legal Issues

US 340B Discount Restrictions By Pharma: HRSA Will Continue To ‘Walk The Walk’ In Opposition

Biden Administration officials pledge ongoing efforts to thwart manufacturer restrictions on 340B drug discounts, but at the same time urge hospitals to be more transparent about how they use the savings.

Pricing Debate Legal Issues
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register